Diaminopropane derived macrocycles as inhibitors of β amyloid production

US7772221B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Lawrence R. Marcin · Bethany, US
• Andrew C. Good · Wallingford, US
• Yong-Jin Wu · Madison, US
• Dmitry S. Zuev · Wallingford, US
• Richard E. Olson · Wilmington, US
• Nenghui Wang · Guilford, US

Key dates

• Filing date: Jan 25, 2008
• Grant date: Aug 10, 2010
• Expiry date: Oct 23, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

There is provided a series of macrocyclic diaminopropanes of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof,wherein R1, R2, R3, m, n, W, X, Y, Z and L as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.